Evidence map›Paper›PMID 32047657›Full record

ArticleNPJ vaccines2020

Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.

Ashley L St John, Hae Woong Choi, Q David Walker, Bruce Blough, Cynthia M Kuhn, Soman N Abraham, Herman F Staats

Abstract read
In one paragraph

Article in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  4. Mast cell activators as adjuvants for intranasal mucosal vaccines.International journal of pharmaceutics · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ashley L St John1Program in Emerging Infectious Diseases, Duke-National University of Singapore, Singapore, 169857 Singapore.ORCID 0000-0001-5098-1044
Hae Woong Choi2Department of Pathology, Duke University Medical Center, Durham, NC 27710 USA.ORCID 0000-0001-9372-1875
Q David Walker5Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710 USA.
Bruce Blough6Center for Drug Discovery, RTI International, Research Triangle Park, Durham, NC 27709 USA.
Cynthia M Kuhn5Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710 USA.
Soman N Abraham1Program in Emerging Infectious Diseases, Duke-National University of Singapore, Singapore, 169857 Singapore.ORCID 0000-0002-1662-2096
Herman F Staats2Department of Pathology, Duke University Medical Center, Durham, NC 27710 USA.ORCID 0000-0003-1039-1087

Funding

Duke KURe ProgramK12DK100024 · NIDDK · DUKE UNIVERSITY · PI Cindy Amundsen · 2013 to 2026
$8.4M
Nasal adjuvant to enhance anti-cocaine vaccinesR21DA029731 · NIDA · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N, STAATS, HERMAN F · 2011 to 2012
$432k
NIDA NIH HHS R21 DA029731NIDDK NIH HHS K12 DK100024
6 · The paper itself

Abstract

Cocaine is one of the most potent and addictive psychostimulants known and there are no available pharmacotherapies to treat cocaine addiction. Here we describe a novel cocaine vaccine employing the mucosal adjuvant and mast cell-activating oligopeptide, mastoparan-7 (M7), to achieve optimal IgA antibody responses in mucosal secretions and effective induction of humoral immunity using a short immunization protocol. This formulation, using a hapten-carrier system to deliver cocaine as antigen, also reduced cocaine penetration of the blood brain barrier and protected mice from its psychoactive effects by reducing cocaine-induced locomotion. Surprisingly, the magnitude of cocaine-specific antibody titers induced by each adjuvant was not the major determinant of functional protection from cocaine challenge. A side-by-side comparison of the two haptens, cocaine and its analog GNC demonstrated that cocaine haptenation resulted in superior functional protection when used in combination with the novel mucosal adjuvant, M7. These results provide a new potential strategy for combatting cocaine addiction through mucosal vaccination.

Indexed as

AddictionConjugate vaccinesVaccines

Identifiers

PMID32047657
PMCPMC7002721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.